| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5578520 | Journal of Pain and Symptom Management | 2017 | 24 Pages |
Abstract
Targeted use of RT in end-of-life cancer care may benefit patients with good PS, but its use may adversely affect patients with poorer PS. Decisions about RT use in this setting should consider likely end-of-life outcomes based on patients' current PS.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
David MD, PhD, Holly G. PhD, Josephine MD, PhD, Paul K. PhD,